Heparin-EGF-like factor

Drug Profile

Heparin-EGF-like factor

Alternative Names: HB-EGF

Latest Information Update: 06 Nov 1995

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Childrens Hospital Boston; Nonindustrial source
  • Developer Nonindustrial source; Scios
  • Class Growth factors; Heparins; Intercellular signalling peptides and proteins
  • Mechanism of Action Heparin epidermal growth factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Respiratory distress syndrome; Respiratory tract disorders; Ulcerative colitis

Most Recent Events

  • 06 Nov 1995 Discontinued-Preclinical for Respiratory distress syndrome in USA (Unknown route)
  • 06 Nov 1995 Discontinued-Preclinical for Respiratory tract disorders in USA (Unknown route)
  • 06 Nov 1995 Discontinued-Preclinical for Ulcerative colitis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top